Top Page
Owens & Minor
(NYSE:OMI)
Owens & Minor (OMI) vs. SPDR S&P 500 ETF (SPY)
Owens & Minor Business Overview & Revenue Model
Owens & Minor Earnings Call Summary
Owens & Minor Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.71B | 10.70B | 10.33B | 9.96B | 9.79B | 8.48B |
| Gross Profit | 1.75B | 2.22B | 2.13B | 1.83B | 1.51B | 1.28B |
| EBITDA | -26.90M | 59.05M | 400.29M | 367.80M | 415.46M | 277.41M |
| Net Income | -1.34B | -362.69M | -41.30M | 22.39M | 221.59M | 29.87M |
Balance Sheet | ||||||
| Total Assets | 4.04B | 4.66B | 5.09B | 5.39B | 3.54B | 3.34B |
| Cash, Cash Equivalents and Short-Term Investments | 32.84M | 49.38M | 243.04M | 69.47M | 55.71M | 83.06M |
| Total Debt | 2.20B | 2.14B | 2.32B | 2.70B | 1.15B | 1.14B |
| Total Liabilities | 4.47B | 4.09B | 4.17B | 4.44B | 2.60B | 2.62B |
| Stockholders Equity | -429.51M | 565.23M | 924.17M | 945.60M | 938.50M | 712.05M |
Cash Flow | ||||||
| Free Cash Flow | -89.99M | -66.67M | 532.82M | 158.42M | 74.49M | 280.03M |
| Operating Cash Flow | -98.97M | 161.50M | 740.71M | 325.01M | 124.18M | 339.22M |
| Investing Cash Flow | -192.88M | -116.53M | -137.25M | -1.80B | -53.63M | 80.07M |
| Financing Cash Flow | 262.48M | -267.60M | -417.33M | 1.50B | -129.48M | -379.39M |
Owens & Minor Technical Analysis
Owens & Minor Risk Analysis
Owens & Minor Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $66.80B | 35.44 | 129.89% | 0.62% | 9.31% | 5.92% | |
70 Outperform | $104.69B | 33.58 | ― | 0.36% | 17.23% | 66.17% | |
69 Neutral | $8.43B | 22.75 | 11.39% | ― | 3.51% | 29.65% | |
65 Neutral | $46.41B | 29.49 | ― | 1.04% | 4.37% | 28.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.80B | -19.71 | -97.70% | ― | ― | ― | |
38 Underperform | $269.94M | ― | -184.47% | ― | -37.09% | -2639.44% |
Owens & Minor Corporate Events
The anticipated sale of assets related to Owens & Minor’s P&HS segment presents significant risks, including potential financial liabilities from divested businesses and obligations to indemnify buyers against unforeseen liabilities. These factors could adversely affect the company’s financial health if post-sale liabilities exceed expectations, impacting cash flows and operational results. Additionally, the divestiture could dilute future earnings if the company fails to compensate for lost revenue and profits, potentially leading to substantial write-offs of goodwill and intangible assets. Such outcomes could materially harm Owens & Minor’s financial condition and operational performance.
Owens & Minor’s recent earnings call was a blend of optimism and caution, reflecting strategic shifts and ongoing challenges. The company announced significant changes, including a major divestiture and a renewed focus on home-based care, which are anticipated to drive future growth. While there were positive developments such as growth in key segments and improved free cash flow, the company also faces hurdles like a decline in adjusted EBITDA and operational issues in its Products & Healthcare Services (P&HS) segment.
Owens & Minor, Inc. is a Fortune 500 global healthcare solutions company that provides essential products and services supporting care from hospitals to homes, with a focus on the home-based care sector. In its third quarter 2025 financial report, Owens & Minor announced a definitive agreement to sell its Products & Healthcare Services segment, positioning itself as a pure-play home-based care business. The company reported a slight increase in revenue to $697.3 million compared to $686.8 million in the same quarter last year. However, it recorded a net loss from continuing operations of $5.6 million, a decline from a net income of $1.3 million in the previous year. Adjusted net income from continuing operations was $19.9 million, down from $28.2 million in the prior year, while adjusted EBITDA was $92.2 million, a decrease from $107.7 million. Looking forward, Owens & Minor reaffirmed its financial guidance for 2025, projecting revenue between $2.76 billion and $2.82 billion, with adjusted EPS ranging from $1.02 to $1.07 and adjusted EBITDA between $376 million and $382 million. The company remains focused on its Patient Direct platform, aiming for sustainable growth and long-term value creation in the home-based care market.
On October 30, 2025, Owens & Minor announced its third-quarter financial results and a significant strategic shift by signing a definitive agreement to sell its Products & Healthcare Services segment. This move positions the company as a pure-play home-based care business, focusing on its Patient Direct platform. The company reported a revenue increase to $697.3 million for the third quarter, with a net loss from continuing operations of $5.6 million. The sale is expected to streamline operations and enhance focus on serving patients with chronic conditions at home, aiming for long-term growth and value creation.
The most recent analyst rating on (OMI) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Owens & Minor stock, see the OMI Stock Forecast page.
On October 7, 2025, Owens & Minor announced a definitive agreement to sell its Products & Healthcare Services segment to Platinum Equity for $375 million in cash and a retained equity stake. This strategic move is part of Owens & Minor’s transformation into a pure-play leader in the home-based care market, allowing the company to focus on its core business and enhance value for stakeholders. The transaction, expected to close by the end of the year, is subject to customary closing conditions and regulatory approvals. The sale will enable Owens & Minor to concentrate on its more profitable segments, leveraging its leading brands and long-standing commitment to patient care to drive consistent revenue and profit growth.
The most recent analyst rating on (OMI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Owens & Minor stock, see the OMI Stock Forecast page.
On September 15, 2025, Owens & Minor announced the resignation of Snehashish Sarkar, their Executive Vice President and Chief Information Officer, effective September 26, 2025. Sarkar, who joined the company in October 2022, has been credited with building a strong global team that is well-equipped to support the company’s strategic goals, indicating a smooth transition despite his departure.
The most recent analyst rating on (OMI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Owens & Minor stock, see the OMI Stock Forecast page.
Owens & Minor faces significant business risks with the contemplated sale of certain assets in its P&HS segment, which could adversely affect its financial stability. The company may encounter substantial retained liabilities from divested businesses and sold assets, along with obligations to indemnify buyers against contingent liabilities. These factors, combined with potential disputes with buyers, could negatively impact Owens & Minor’s financial position, operations, and cash flows. Additionally, the divestiture could lead to a dilutive impact on future earnings if the company fails to offset the loss of revenue and profits, potentially resulting in significant write-offs and adversely affecting its financial condition.
Owens & Minor, Inc. is a Fortune 500 global healthcare solutions company that provides essential products and services supporting care from hospitals to homes, with a focus on delivering comfort and confidence in healthcare environments.
Owens & Minor’s recent earnings call highlighted a strategic shift towards becoming a pure-play Patient Direct business. The sentiment was generally positive, focusing on growth in specific categories and effective working capital management. However, the company faces challenges such as costs from the Rotech acquisition, disruptions in the diabetes segment, and potential increases in stranded costs.
On August 11, 2025, Owens & Minor reported its second-quarter financial results, highlighting the classification of its Products & Healthcare Services segment as discontinued operations due to an impending sale. The company’s continuing operations, primarily the Patient Direct segment, showed solid performance and growth, with revenue increasing to $681.9 million from $660.4 million in the same quarter of the previous year. Despite a net loss from continuing operations, the adjusted net income and EBITDA showed improvement, reflecting the company’s strategic focus on the Patient Direct business. CEO Ed Pesicka expressed optimism about the company’s future as a pure-play Patient Direct business, supported by favorable demographic trends.
The most recent analyst rating on (OMI) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Owens & Minor stock, see the OMI Stock Forecast page.